Site Map   |  Contact Us  |  Search
TNKase TNKase

TNKase Dosing and Administration
Investigate the Molecule
Clinical Data
Publications and Resources
Relevant Links
Product Return and Replacement
Prescribing Information


   Get A Free Dosing Card

Genentech is neither affiliated with nor endorses the following organizations.

American Association of Critical Care Nurses (AACN)
American College of Cardiology (ACC)
American College of Emergency Physicians (ACEP)
American College of Physicians (ACP)
American College of Chest Physicians (ACCP)
American Heart Association (AHA)
American Medical Association (AMA)
American Society of Health-System Pharmacists (ASHP)
American Society of Nuclear Cardiology (ASNC)
Emergency Nurses Association (ENA)
European Society of Cardiology (ESC)
Society for Cardiac Angiography and Interventions (SCAI)

Back to top

Journals and Publications
American Heart Journal
American Journal of Critical Care Nursing (AACN)
Annals of Emergency Medicine
Cardiovascular Research
Clinical Cardiology
Journal of the American College of Cardiology (JACC)
Journal of the American Medical Association (JAMA)
Journal of Emergency Nursing
Journal of Invasive Cardiology
Journal of Interventional Cardiology
Journal of Nuclear Cardiology
Journal of Thoracic and Cardiovascular Surgery
New England Journal of Medicine

Back to top

Cardiology Resources
ACC/AHA Practice Guidelines
Cleveland Clinic Heart Center
Clinical Trial Results
Food and Drug Administration
Medical Matrix
Medscape Cardiology
TIMI Study Group
The Heart
The Merck Manual, Home Edition
Stanford Interventional Cardiology

Back to top

CenterWatch Clinical Trials Listing Service
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)

Back to top

For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms.

Important Safety Information
TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information].

The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately.

In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information].

Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown.

Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered.

Please see full Prescribing Information for additional important safety information.

TNKase Dosing and Administration Investigate the Molecule Clinical Data Publications and Resources
Relevant Links Product Return and Replacement Full Package Insert Opt Out Home Terms and Conditions Privacy Policy

Please see TNKase full Prescribing Information. TNKase® (Tenecteplase). Activase® (Alteplase, recombinant).

© 2014 Genentech, Inc. All rights reserved. TNK0000729208
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080-4990